Tag: scPharmaceuticals

scPharmaceuticals Announces FDA Acceptance of FUROSCIX® New Drug Application Resubmission

FDA sets PDUFA date of December 30, 2020 BURLINGTON, Mass.–(BUSINESS WIRE)–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare […]

scPharmaceuticals Inc. Announces Recent Progress on FUROSCIX® and Highlights Corporate Objectives

Successful completion of human factors program ahead of FUROSCIX NDA resubmission BURLINGTON, Mass.–(BUSINESS WIRE)–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, […]